Search | VHL Regional Portal

Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab.

Gordilho, J O; Miyamoto, D; Maruta, C W; Santo, R M; Mahmoud, A; Navarro-Rodriguez, T; Werneck-Silva, A L; de Aguiar, L M; Borges, I C; Santi, C G; Aoki, V.

J Eur Acad Dermatol Venereol ; 38(1): e45-e47, 2024 Jan.

Article in English | MEDLINE | ID: mdl-37565448

Subject(s)

Epidermolysis Bullosa Acquisita , Epidermolysis Bullosa , Rituximab , Humans , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/drug therapy , Immunoglobulin G/blood , Rituximab/therapeutic use

See more details

SEND TO:

Export

RSS

XML

SELECTION OF CITATIONS

List items (0)
Clear list

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL